Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2 Arm, Phase II Controlled Randomized Trial Comparing Efficacy and Safety of Abiraterone and Abiraterone Associated With of Ablative Radiation Therapy in Patients With Oligometastatic Castration Resistant Prostate Cancer (ARTO Trial)

NCT03449719 is registered in ClinicalTrials.gov with Lorenzo Livi as lead sponsor.

NCT NCT03449719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03449719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2 Arm, Phase II Controlled Randomized Trial Comparing Efficacy and Safety of Abiraterone and Abiraterone Associated With of Ablative Radiation Therapy in Patients With Oligometastatic Castration Resistant Prostate Cancer (ARTO Trial)
Lead sponsor
Lorenzo Livi
Phase
Not applicable
Overall status
Unknown status
Start date
May 1, 2018
Completion date
May 1, 2022
Enrollment
174 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rate of psa response in oligometastatic,crpc undergoing sbrt in combination with abiraterone acetate (aa), compared to patients treated with aa alone